Antiproliferative effect of ABT-869 on various leukemia cell lines
| Cell line . | Designation/mutation . | IC50, nM . | |
|---|---|---|---|
| alamarBlue assay* . | Viability† . | ||
| MV-4-11 | AML—FLT3-ITD | 4 | 10 |
| Kasumi-1 | AML-ETO (SCF-KIT loop; KIT N822K) | 16 | ND |
| RS4;11 | ALL—wt-FLT3 | 4100 | ND |
| Jurkat | ALL—FLT3-negative | 4200 | ND |
| HL-60 | APL—FLT3-negative | ≈8000 | > 10 000‡ |
| NB4 | APL—PML-RARα | ND | > 10 000 |
| KG-1 | AML—wt-FLT3 (FGF-FGFR loop) | > 100 | > 10 000 |
| K562 | CML—Bcr-Abl FLT3-negative | > 5000 | > 10 000 |
| MOLM-13 | AML—FLT3-ITD | 6 | 10-100 |
| Cell line . | Designation/mutation . | IC50, nM . | |
|---|---|---|---|
| alamarBlue assay* . | Viability† . | ||
| MV-4-11 | AML—FLT3-ITD | 4 | 10 |
| Kasumi-1 | AML-ETO (SCF-KIT loop; KIT N822K) | 16 | ND |
| RS4;11 | ALL—wt-FLT3 | 4100 | ND |
| Jurkat | ALL—FLT3-negative | 4200 | ND |
| HL-60 | APL—FLT3-negative | ≈8000 | > 10 000‡ |
| NB4 | APL—PML-RARα | ND | > 10 000 |
| KG-1 | AML—wt-FLT3 (FGF-FGFR loop) | > 100 | > 10 000 |
| K562 | CML—Bcr-Abl FLT3-negative | > 5000 | > 10 000 |
| MOLM-13 | AML—FLT3-ITD | 6 | 10-100 |
ND indicates not determined for this cell line; ALL, acute lymphoblastic leukemia; AML, acute myelocytic leukemia; APL, acute promyelocytic leukemia; and CML, chronic myelogenous leukemia.
*alamarBlue assay determines viability of cells by mitochondrial metabolism of MTT-like dye after 72-hour exposure to compounds.
†Viability determined by the trypan blue (TB) exclusion assay after 48-hour compound exposure.
‡Concentration is the maximum tested.